SCHEMBL12019256

SCHEMBL12019256

O=CCNC(=O)Cc1ccccn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
GLS O94925 1/20 0.46
HPGD P15428 2/20 0.46
RECQL P46063 1/20 0.46
ALOX15 P16050 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5032696 0.80 POLB (0.58) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL6426566 0.79 POLB (0.60) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL30861597 0.79 POLB (0.60) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL6796071 0.78 PDE5A (0.55) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL10572999 0.77 POLB (0.77) POLBSMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL7746725 0.77 POLB (0.59) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL10272684 0.77 POLB (0.55) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL2028409 0.77 CA1 (0.69) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL1516476 0.76 POLB (0.54) POLBSMN1; SMN2CA1CA2CA5A
SCHEMBL24015947 0.76 SMN1; SMN2 (0.53) POLBSMN1; SMN2CA1CA2CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220567-A1 BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS SCHERING CORPORATION 2012-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220567-A1 BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS SCD, SCD5, CPT1A POLB 1600/4885SMN1; SMN2 1278/4885CA1 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.